Premium
PMPC Modified PAMAM Dendrimer Enhances Brain Tumor‐Targeted Drug Delivery
Author(s) -
Ban Jiamin,
Li Sidi,
Zhan Qi,
Li Xuepin,
Xing Huike,
Chen Ning,
Long Lixia,
Hou Xin,
Zhao Jin,
Yuan Xubo
Publication year - 2021
Publication title -
macromolecular bioscience
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.924
H-Index - 105
eISSN - 1616-5195
pISSN - 1616-5187
DOI - 10.1002/mabi.202000392
Subject(s) - nanocarriers , cytotoxicity , doxorubicin , in vivo , dendrimer , pharmacology , phosphorylcholine , drug delivery , blood–brain barrier , chemistry , glioma , biocompatibility , brain tumor , drug , targeted drug delivery , drug carrier , in vitro , cancer research , chemotherapy , medicine , pathology , biology , biochemistry , central nervous system , microbiology and biotechnology , organic chemistry
The excellent biocompatibility drug delivery system for effective treatment of glioma is still greatly challenged by the existence of blood–brain barrier, blood–brain tumor barrier, and the tissue toxicity caused by chemotherapy drugs. In this study, poly(2‐methacryloyloxyethyl phosphorylcholine) (PMPC) is used for the first time for modifying third‐generation poly(amidoamine) (PAMAM) to enhance their brain tumor‐targeted drug delivery ability as well as simultaneously reducing the toxicity of PAMAM dendrimers and the tissue toxicity of the loaded doxorubicin (DOX). The cytotoxicity, the therapeutic ability in vitro, and the brain tumor‐targeted ability of the PMPC modified PAMAM nanoparticles are further studied. Results indicate that PMPC, as a dual‐functional modifier, can significantly reduce the cytotoxicity of PAMAM dendrimers, while efficiently target the brain tumor. In addition, the therapeutic effect of DOX‐loaded PAMAM‐PMPC in mice inoculated with U‐87 is also studied in vivo. In comparison with DOX solution, DOX‐loaded PAMAM‐PMPC alleviates weight loss of tumor‐inoculated mice and reduces the cardiotoxicity of DOX. The tumor growth inhibition, in vivo, is significantly increased up to (80.76 ± 1.66)%. In conclusion, this strategy of PMPC dual‐functional targeted nanocarrier provides a new method for the delivery of chemotherapeutic drugs to treat glioma.